This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
How well are CLL patients responding to the COVID-19 vaccines? There are several trials currently accruing patients to study this exact question. CLL Society will continue to share the most up-to-date information about these various trials as more information becomes available. We are all hopeful that there will be answers to our questions very soon. Click here to find out more about these ongoing trials!
In Case You Missed It:
Coming soon! On-demand recording of our March 26th COVID-19 Virtual Community Meeting: Contagion, Variants, and Vaccines. Stay tuned!
COVID-19 Updated Page
Variants of the SARS-CoV-2 virus are causing concern, not only for the effectiveness of vaccine coverage, but also for the effectiveness of monoclonal antibodies to provide protection-post exposure. To stay up to date, please see our revised webpage on this topic: Anti-SARS-CoV-2 Monoclonal Antibodies for Chronic Lymphocytic Leukemia (CLL) and Other High-Risk Patients Who Test Positive for COVID-19.
CLL Society Advocacy Efforts
In January 2021, CLL Society spearheaded several advocacy efforts pertaining to COVID-19 vaccine prioritization for blood cancer patients. While CLL Society can’t take all the credit for this good news, we are excited to report that CLL patients are now eligible to receive the vaccination in 46 states! To learn more and see if you live in one of the four outlying states, see our Summary of COVID-19 Vaccine Advocacy Efforts here. Thanks to everyone who participated in our vaccination prioritization campaign.
ASH 2020: CLL Society’s Chairman of the Board, Steven Bloom, interviewed Dr. Ian Flinn on the use of obinutuzumab and bendamustine as debulking agents prior to treatment of CLL with venetoclax. They discuss mitigating the risk of tumor lysis syndrome so that venetoclax can be administered safely in an outpatient setting. Learn more here.
CAR-T Ed Forum: The Basic Science and Latest Data
Please join CLL Society for a two-hour event on Wednesday, April 21st (10:00 AM PT, 11:00 AM MT, 12:00 PM CT, and 1:00 PM ET) as we continue to strengthen your learning about CAR-T therapy. Dr. John Pagel will define CAR-T, explain how it works, and share where this treatment might be headed in the future. Dr. Tanya Siddiqi’s ongoing CAR-T clinical trial at the City of Hope National Medical Center is well known. She will be on-hand to present her current data showing the success of CAR-T therapy in CLL, both with and without ibrutinib. Dr. Larry & Sharon Saltzman will share their CLL CAR-T journey from the doctor-turned-patient perspective and the caregiver’s point of view. Learn more and register here!
NeedyMeds: The webinar, “Copay or Premium Financial Assistance in Less Than Five Minutes” is taking place today at 11 AM PT / 2 PM ET. Find out about this event and other virtual events on our Upcoming Education Page here.
National Comprehensive Cancer Network (NCCN) Webinar: Please consider registering for a free NCCN webinar for people with chronic lymphocytic leukemia (CLL), their caregivers, and their families. CLL Society’s Dr. Brian Koffman and Dr. Jennifer Brown will present, “Know What Your Doctors Know: Chronic Lymphocytic Leukemia (CLL)” on April 21st & April 26th. Learn more here.
The PAN Foundation helps federally and commercially insured people living with life-threatening, chronic, and rare diseases with out-of-pocket costs for their prescribed medications. PAN’s chronic lymphocytic leukemia (CLL) patient assistance fund can provide up to $8,700 per year in financial assistance to pay for the deductibles, co-pays, and coinsurance costs associated with CLL treatment. Funds are available for CLL patients.
The LLS Susan Lang Pre CAR T-cell Therapy Travel Assistance program is available to CLL patients with significant financial need. The fund provides financial assistance to patients diagnosed with blood cancer who are being evaluated to receive CAR T cell therapy within a clinical trial.
You can find out about both programs and other forms of financial assistance on the CLL Society website here.
Your input is valuable! Please consider visiting our Paid Research Opportunities page to learn about surveys and interviews for CLL patients and caregivers.
Please Support CLL Society
CLL Society is the only CLL-specific, physician-curated public charity dedicated to meeting the unmet needs of CLL patients and their caregivers which holds the GuideStar Platinum Seal of Transparency.
We are all in this together.
Co-Founder & Communications Director
CLL Society Support Group Meetings Coming Up!
CLL Society Support Group meetings have moved to a virtual platform for most locations due to the threat of coronavirus. Support group members will receive an invitation to register for the meeting from the support group facilitator. If you are new to the group, please contact the RSVP email for the Support Group in your region. Once it is safe again, we will resume in-person meetings.
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.